<DOC>
	<DOCNO>NCT00915187</DOCNO>
	<brief_summary>To examine safety immunogenicity two formulation liposomal adjuvant / delivery system ( VaxiSomeTM=CCS-Cholesterol [ CCS/C ] ) , combine commercial influenza vaccine elderly healthy population give intramuscularly ( IM ) .</brief_summary>
	<brief_title>Safety Immunogenicity Study Intramuscular CCS/C-adjuvanted Influenza Vaccine Elderly</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>65 year age old , mentally competent , willing able give write informed consent prior study entry , male female ; able comply study requirement ; stable good health determine medical history ; physical examination ; clinical judgment investigator . Have adequate renal function ( renal clearance &gt; 30ml/min ) Have normal liver function ( hepatic transaminase [ ALT AST ] &lt; 43 U/L ) Have hemoglobin &gt; 11.5 g/L Any serious chronic acute disease ( judgment investigator ) include limited : cancer , except localize skin cancer ; Advanced congestive heart failure ; Acute exacerbation Chronic obstructive pulmonary disease ( COPD ) ; Autoimmune disease , Acute progressive hepatic disease ; Acute progressive renal disease renal clearance &lt; 30ml/min ; Severe neurological psychiatric disorder ; History Guillain Barr√© syndrome ; Severe asthma . Clinically significant symptom neurological disease ; untreated hypertension ; increase liver enzymes . History anaphylactic reaction and/or serious allergic reaction follow vaccination</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Vaccination , influenza prevention</keyword>
</DOC>